Skip to main content

Table 1 IQ scores of patients and controls at each time period

From: The impact of therapy for childhood acute lymphoblastic leukaemia on intelligence quotients; results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI

  Number tested Mean adjusted IQ* (SD) Difference in
means
(95% CI)
t-test
p-value
  Controls    Patients    Controls Patients   
FSIQ       
   5 months    157    284 102.5
(14)
101.0
(15)
1.4
(-1.5 : 4.4)
   0.3
   3 years    173    366 104.8
(14)
97.7
(16)
7.1
(4.4 : 9.8)
   < 0.0001
   5 years    132    289 105.2
(15)
100.0
(16)
5.2
(1.9 : 8.5)
   0.002
VIQ       
   5 months    158    287 102.0
(14)
99.6
(15)
2.3
(-0.5 : 5.2)
   0.1
   3 years    173    366 103.4
(15)
97.7
(15)
5.7
(3.1 : 8.4)
   < 0.0001
   5 years    132    289 103.2
(14)
99.6
(15)
3.6
(0.5 : 6.7)
   0.02
PIQ       
   5 months    160    299 102.5
(15)
102.0
(16)
0.5
(-2.5 : 3.5)
   0.7
   3 years    173    368 105.5
(15)
98.2
(16)
7.3
(4.5 : 10.1)
   < 0.0001
   5 years    132    289 106.4
(16)
100.5
(17)
5.9
(2.5 : 9.3)
   0.0006
  1. *IQ adjusted for test by subtracting:
  2. 7.15 from each WPPSI-R full IQ
  3. 3.79 from each WPPSI-R verbal IQ.
  4. 8.74 from each WPPSI-R performance IQ.